×
About 50,882 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,067 results

Acute myeloid leukemia: current progress and future directions.
https://doi.org/10.1038/s41408-021-00425-3 10.1002/ajh.24246 10.1016/S0140-6736(18)31041-9 10.1001/jamaoncol.2015.0617 10.1016/j.clml.2014.08.006 10.1056/NEJMra1406184 10.1056/NEJMoa0901409 10.1056/NEJMoa0904544 10.1200/JCO.2008.18.6130 10.1056/NEJMoa1300874 10.1182/blood-2016-09-736686 10.1200/JCO.2016.67.1982 10.1016/S1470-2045(15)00193-X 10.1002/ajh.23795 10.1182/blood-2019-126014 10.1200/JCO.2010.31.4310 10.1182/blood-2013-01-466706 10.1016/S1470-2045(14)70281-5 10.1056/NEJMoa1112304 10.1056/NEJMoa1301689 10.1038/nature10738 10.1056/NEJMoa1516192 10.1182/blood-2009-11-254441 10.1200/JCO.2013.52.3480 10.1182/hematology.2019000059 10.1158/2159-8290.CD-19-1011 10.1200/JCO.2011.38.9429 10.1097/01.COT.0000390348.25801.68 10.1182/blood-2015-01-621664 10.1016/S1470-2045(15)00201-6 10.1182/blood-2016-08-733196 10.6004/jnccn.2019.0028 10.1002/ajh.24072 10.1002/cncr.25670 10.1182/blood-2012-06-431122 10.1182/blood-2014-05-578070 10.1016/j.bbmt.2015.10.023 10.1056/NEJMoa074306 10.1038/leu.2008.375 10.1002/cncr.30203 10.1080/10428194.2017.1422864 10.1002/cncr.32566 10.1200/JCO.2011.35.4894 10.1056/NEJMoa1005143 10.1200/JCO.2011.40.6652 10.1200/JCO.2010.30.7926 10.1200/JCO.2011.41.5505 10.1182/blood-2005-09-3640 10.1200/JCO.2006.06.9500 10.1182/blood-2005-04-1466 10.1182/blood.V124.21.8.8 10.1200/JCO.19.00416 10.1038/nm.3788 10.1056/NEJMoa1605949 10.1172/JCI129126 10.1056/NEJMoa1716863 10.1182/blood-2014-05-577593 10.1001/jama.2015.9452 10.1001/jama.2015.9643 10.1002/cncr.30361 10.1001/jamaoncol.2020.4600 10.1200/JCO.19.03011 10.1200/JCO.2008.20.1533 10.1182/blood-2012-06-435669 10.1182/blood-2012-11-468348 10.1200/JCO.2011.35.0371 10.1182/blood-2009-03-213389 10.1016/0002-9343(86)90617-0 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G 10.1182/blood-2004-04-1550 10.1200/JCO.2001.19.18.3852 10.1182/blood.V94.4.1192 10.1182/blood-2002-02-0632 10.1182/blood-2010-02-269621 10.1182/blood-2010-08-302950 10.1182/blood-2018-05-851824 10.1182/bloodadvances.2019001278 10.1038/sj.leu.2404272 10.1002/cncr.32196 10.3324/haematol.2019.229583 10.1016/S1470-2045(18)30295-X 10.1200/JCO.2004.07.012 10.1182/blood-2012-05-431486 10.1056/NEJM199410063311402 10.1200/JCO.2012.47.4874 10.1182/blood.V88.8.2841.bloodjournal8882841 10.1182/blood.V87.5.1710.1710 10.1002/cncr.21543 10.1056/NEJMoa1010222 10.1200/JCO.2013.51.8571 10.1182/bloodadvances.2018026625 10.1182/blood.V93.8.2478 10.1200/JCO.2012.42.2964 10.1182/blood.V122.21.2692.2692 10.1038/sj.leu.2403336 10.1200/JCO.2011.37.1286 10.1002/cncr.30883 10.1182/blood-2015-01-623447 10.1046/j.1365-2141.1998.00948.x 10.1200/JCO.2009.23.2652 10.1200/JCO.2011.40.3642 10.1200/JCO.2008.20.6490 10.1016/S0140-6736(12)60485-1 10.1182/blood.V118.21.79.79 10.1016/S1470-2045(14)70289-X 10.1200/JCO.2012.43.0132 10.1200/JCO.2009.26.4648 10.1182/blood-2020-134300 10.1182/blood-2015-07-627323 10.1056/NEJMoa061094 10.1056/NEJMoa1614359 10.1182/blood-2018-99-118492 10.1016/S1470-2045(20)30455-1 10.1200/JCO.19.03345 10.1182/blood-2015-08-662130 10.1016/j.leukres.2018.03.006 10.1002/cncr.21723 10.1182/blood-2010-03-276485 10.1182/blood-2012-06-436055 10.1016/j.clml.2015.11.016 10.1093/cid/ciz194 10.2165/00002512-200522110-00004 10.1002/cncr.22496 10.1073/pnas.1002650107 10.1016/S2352-3026(19)30030-4 10.1182/blood.2019004143 10.1016/S2352-3026(18)30132-7 10.1002/cncr.29367 10.1158/2159-8290.CD-13-0609 10.1158/2159-8290.CD-16-0313 10.1200/JCO.18.01600 10.1182/blood-2018-08-868752 10.1056/NEJMoa2012971 10.1182/blood.2020004856 10.1016/S2352-3026(20)30210-6 10.1002/ajh.25198 10.1182/blood-2018-99-110976 10.1200/JCO.2010.30.5961 10.1182/blood-2013-12-540971 10.1200/JCO.2017.77.6112 10.1158/2643-3230.BCD-20-0007 10.1038/s41375-018-0312-9 10.1158/1078-0432.CCR-19-0365 10.1200/JCO.2011.40.7783 10.1182/blood-2019-131055 10.1182/blood-2019-125579 10.1016/j.cell.2009.05.046 10.1016/j.cell.2009.05.045 10.1056/NEJMoa1807315 10.1056/NEJMoa2004444 10.1182/blood-2018-10-879866 10.1056/NEJMoa1902688 10.1111/bjh.16265 10.1002/ajh.24767 10.1002/cncr.31296 10.1001/jama.2009.813 10.1046/j.1365-2141.2002.03724.x 10.1016/j.clml.2012.03.003 10.1016/S1470-2045(17)30416-3 10.1182/blood-2017-04-779447 10.1182/blood.V126.23.323.323 10.1182/blood-2019-130362 10.1056/NEJMoa1716984 10.1182/bloodadvances.2020001503 10.1182/blood-2014-03-560557 10.1182/blood-2019-126262 10.1038/s41591-020-0910-8 10.1182/blood-2019-128501 10.1182/blood-2018-99-111914 10.1182/blood-2018-99-111915
Blood Cancer Journal; Kantarjian H, Kadia T et. al.

Feb 23rd, 2021 - Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FL...

Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refrac...
https://doi.org/10.1016/j.clml.2021.01.011
Clinical Lymphoma, Myeloma & Leukemia; Reid JH, Marini BL et. al.

Feb 22nd, 2021 - Relapsed/refractory acute myeloid leukemia (AML) confers a poor prognosis, and there is no single standard of care first-line salvage regimen. FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor) is a common salvage regimen wi...

Identifying COVID-19 Risk Through Observational Studies to Inform Control Measures.
https://doi.org/10.1002/cam4.3665
JAMA Garg R, Allen KJH et. al.

Feb 22nd, 2021 - Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with lo...

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with ...
https://doi.org/10.1182/bloodadvances.2020003855
Blood Advances; Löwenberg B, Pabst T et. al.

Feb 22nd, 2021 - Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in ne...

Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic...
https://doi.org/10.1016/j.leukres.2021.106535
Leukemia Research; Shimizu H, Yokohama A et. al.

Feb 21st, 2021 - Additional cytogenetic abnormality (ACA) acquisition at relapse has been recognized as clonal evolution at the cytogenetic level, and has a significant prognostic impact on relapsed acute myeloid leukemia (AML) patients. We retrospectively investi...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,161 results

Novel Therapies and New Indications for Use in Treatment of Hematologic Malignancies
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/novel-therapies-and-new-indications-for-use-in-treatment-of-hematologic-malignancies/

Feb 24th, 2021 - Selinexor: On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at leas...

Acute myeloid leukemia: current progress and future directions.
https://doi.org/10.1038/s41408-021-00425-3 10.1002/ajh.24246 10.1016/S0140-6736(18)31041-9 10.1001/jamaoncol.2015.0617 10.1016/j.clml.2014.08.006 10.1056/NEJMra1406184 10.1056/NEJMoa0901409 10.1056/NEJMoa0904544 10.1200/JCO.2008.18.6130 10.1056/NEJMoa1300874 10.1182/blood-2016-09-736686 10.1200/JCO.2016.67.1982 10.1016/S1470-2045(15)00193-X 10.1002/ajh.23795 10.1182/blood-2019-126014 10.1200/JCO.2010.31.4310 10.1182/blood-2013-01-466706 10.1016/S1470-2045(14)70281-5 10.1056/NEJMoa1112304 10.1056/NEJMoa1301689 10.1038/nature10738 10.1056/NEJMoa1516192 10.1182/blood-2009-11-254441 10.1200/JCO.2013.52.3480 10.1182/hematology.2019000059 10.1158/2159-8290.CD-19-1011 10.1200/JCO.2011.38.9429 10.1097/01.COT.0000390348.25801.68 10.1182/blood-2015-01-621664 10.1016/S1470-2045(15)00201-6 10.1182/blood-2016-08-733196 10.6004/jnccn.2019.0028 10.1002/ajh.24072 10.1002/cncr.25670 10.1182/blood-2012-06-431122 10.1182/blood-2014-05-578070 10.1016/j.bbmt.2015.10.023 10.1056/NEJMoa074306 10.1038/leu.2008.375 10.1002/cncr.30203 10.1080/10428194.2017.1422864 10.1002/cncr.32566 10.1200/JCO.2011.35.4894 10.1056/NEJMoa1005143 10.1200/JCO.2011.40.6652 10.1200/JCO.2010.30.7926 10.1200/JCO.2011.41.5505 10.1182/blood-2005-09-3640 10.1200/JCO.2006.06.9500 10.1182/blood-2005-04-1466 10.1182/blood.V124.21.8.8 10.1200/JCO.19.00416 10.1038/nm.3788 10.1056/NEJMoa1605949 10.1172/JCI129126 10.1056/NEJMoa1716863 10.1182/blood-2014-05-577593 10.1001/jama.2015.9452 10.1001/jama.2015.9643 10.1002/cncr.30361 10.1001/jamaoncol.2020.4600 10.1200/JCO.19.03011 10.1200/JCO.2008.20.1533 10.1182/blood-2012-06-435669 10.1182/blood-2012-11-468348 10.1200/JCO.2011.35.0371 10.1182/blood-2009-03-213389 10.1016/0002-9343(86)90617-0 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G 10.1182/blood-2004-04-1550 10.1200/JCO.2001.19.18.3852 10.1182/blood.V94.4.1192 10.1182/blood-2002-02-0632 10.1182/blood-2010-02-269621 10.1182/blood-2010-08-302950 10.1182/blood-2018-05-851824 10.1182/bloodadvances.2019001278 10.1038/sj.leu.2404272 10.1002/cncr.32196 10.3324/haematol.2019.229583 10.1016/S1470-2045(18)30295-X 10.1200/JCO.2004.07.012 10.1182/blood-2012-05-431486 10.1056/NEJM199410063311402 10.1200/JCO.2012.47.4874 10.1182/blood.V88.8.2841.bloodjournal8882841 10.1182/blood.V87.5.1710.1710 10.1002/cncr.21543 10.1056/NEJMoa1010222 10.1200/JCO.2013.51.8571 10.1182/bloodadvances.2018026625 10.1182/blood.V93.8.2478 10.1200/JCO.2012.42.2964 10.1182/blood.V122.21.2692.2692 10.1038/sj.leu.2403336 10.1200/JCO.2011.37.1286 10.1002/cncr.30883 10.1182/blood-2015-01-623447 10.1046/j.1365-2141.1998.00948.x 10.1200/JCO.2009.23.2652 10.1200/JCO.2011.40.3642 10.1200/JCO.2008.20.6490 10.1016/S0140-6736(12)60485-1 10.1182/blood.V118.21.79.79 10.1016/S1470-2045(14)70289-X 10.1200/JCO.2012.43.0132 10.1200/JCO.2009.26.4648 10.1182/blood-2020-134300 10.1182/blood-2015-07-627323 10.1056/NEJMoa061094 10.1056/NEJMoa1614359 10.1182/blood-2018-99-118492 10.1016/S1470-2045(20)30455-1 10.1200/JCO.19.03345 10.1182/blood-2015-08-662130 10.1016/j.leukres.2018.03.006 10.1002/cncr.21723 10.1182/blood-2010-03-276485 10.1182/blood-2012-06-436055 10.1016/j.clml.2015.11.016 10.1093/cid/ciz194 10.2165/00002512-200522110-00004 10.1002/cncr.22496 10.1073/pnas.1002650107 10.1016/S2352-3026(19)30030-4 10.1182/blood.2019004143 10.1016/S2352-3026(18)30132-7 10.1002/cncr.29367 10.1158/2159-8290.CD-13-0609 10.1158/2159-8290.CD-16-0313 10.1200/JCO.18.01600 10.1182/blood-2018-08-868752 10.1056/NEJMoa2012971 10.1182/blood.2020004856 10.1016/S2352-3026(20)30210-6 10.1002/ajh.25198 10.1182/blood-2018-99-110976 10.1200/JCO.2010.30.5961 10.1182/blood-2013-12-540971 10.1200/JCO.2017.77.6112 10.1158/2643-3230.BCD-20-0007 10.1038/s41375-018-0312-9 10.1158/1078-0432.CCR-19-0365 10.1200/JCO.2011.40.7783 10.1182/blood-2019-131055 10.1182/blood-2019-125579 10.1016/j.cell.2009.05.046 10.1016/j.cell.2009.05.045 10.1056/NEJMoa1807315 10.1056/NEJMoa2004444 10.1182/blood-2018-10-879866 10.1056/NEJMoa1902688 10.1111/bjh.16265 10.1002/ajh.24767 10.1002/cncr.31296 10.1001/jama.2009.813 10.1046/j.1365-2141.2002.03724.x 10.1016/j.clml.2012.03.003 10.1016/S1470-2045(17)30416-3 10.1182/blood-2017-04-779447 10.1182/blood.V126.23.323.323 10.1182/blood-2019-130362 10.1056/NEJMoa1716984 10.1182/bloodadvances.2020001503 10.1182/blood-2014-03-560557 10.1182/blood-2019-126262 10.1038/s41591-020-0910-8 10.1182/blood-2019-128501 10.1182/blood-2018-99-111914 10.1182/blood-2018-99-111915
Blood Cancer Journal; Kantarjian H, Kadia T et. al.

Feb 23rd, 2021 - Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FL...

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) after one participant developed acute myeloid leukemia (AML) and another developed myelodysplastic syndrome (MDS). The sponsoring company, bluebird b...

Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refrac...
https://doi.org/10.1016/j.clml.2021.01.011
Clinical Lymphoma, Myeloma & Leukemia; Reid JH, Marini BL et. al.

Feb 22nd, 2021 - Relapsed/refractory acute myeloid leukemia (AML) confers a poor prognosis, and there is no single standard of care first-line salvage regimen. FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor) is a common salvage regimen wi...

Identifying COVID-19 Risk Through Observational Studies to Inform Control Measures.
https://doi.org/10.1002/cam4.3665
JAMA Garg R, Allen KJH et. al.

Feb 22nd, 2021 - Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with lo...

see more →

News  1,493 results

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) after one participant developed acute myeloid leukemia (AML) and another developed myelodysplastic syndrome (MDS). The sponsoring company, bluebird b...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

Black Race Linked to Poorer Survival in AML
https://www.medscape.com/viewarticle/942309

Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...

Beat AML: Precision Medicine Superior to SOC
https://www.medscape.com/viewarticle/940843

Nov 11th, 2020 - Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial. The 30-day mortality rates were 3.7% versus 20.4% in 224 patients who enr...

see more →

Patient Education  7 results see all →